Interleukin-17 inhibition in psoriatic arthritis

Helliwell, Philip S.; Coates, Laura C.

doi:10.1016/s0140-6736(15)61170-9

Cited by 5 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CXCR3 was 5.3-fold greater ( p = 0.011) in patients with PsA than in patients with OA, 32.3-fold greater ( p = 1.2 × 10 −6 ) than in patients with gout, and 3.9-fold greater ( p = 0.02) than in patients with RA. IL-17A has previously been shown to play an important role in the pathogenesis of PsA, and anti-IL-17A monoclonal antibodies have recently been approved for clinical use [17, 18]. IL-17A gene expression was explored here to gain insight into how the combination of these cytokines/chemokines acts together in PsA.…”

Section: Resultsmentioning

confidence: 99%

Differential gene and protein expression of chemokines and cytokines in synovial fluid of patients with arthritis

et al. 2016

View full text Add to dashboard Cite

BackgroundPsoriatic arthritis (PsA), an inflammatory musculoskeletal disease, develops in approximately 30% of patients with psoriasis. Previously, chemokine (C-X-C motif) ligand 10 (CXCL10) was identified as a predictive biomarker of PsA in patients with psoriasis and was reduced after development of PsA. The purpose of the present study was to explore messenger RNA (mRNA) and protein expression of CXCL10 and its receptor, chemokine (C-X-C motif) receptor 3 (CXCR3), in the joints of patients with PsA to gain insight into their role in the pathogenesis of the disease.MethodsSera from 47 patients with PsA and 33 healthy control subjects were compared for expression of CXCL10 by Luminex assay. Synovial fluid (SF) was obtained from patients with PsA (n = 40), osteoarthritis (OA; n = 14), gout (n = 8), and rheumatoid arthritis (RA; n = 11) during clinical care. SF mRNA and protein expression of CXCL10, interleukin-17A (IL-17A), CXCR3, TBX21, RORC and/or interferon γ (IFNγ) were compared among the above-mentioned disease groups, as well as in paired SF and serum samples from patients with PsA using real-time polymerase chain reaction and Luminex assays, respectively.ResultsSerum CXCL10 was significantly higher in patients with PsA than in control subjects (p = 0.0007). CXCL10, IL-17A, and TBX21 expression were elevated in SF cells of patients with PsA compared with those of patients with OA and gout, but not those of patients with RA. CXCR3 and RORC were elevated in PsA SF cells compared with all other patient groups. Concordant results were obtained for CXCL10 and IL-17A protein expression. IFNγ was elevated in PsA SF compared with OA SF (p = 0.015). CXCL10 protein expression was substantially increased in SF (median 7283.9 pg/ml, interquartile range [IQR] 1330–10,362 pg/ml) compared with paired serum samples (median 282.06, IQR 180.7–395.8 pg/ml; p = 0.001), whereas IFNγ was significantly reduced (SF median 6.03 pg/ml, IQR 4.47–8.94 pg/ml; versus serum median 23.70 pg/ml, IQR 3.2–104.6 pg/ml; p = 0.001).ConclusionsCXCL10 may have an important etiological role in PsA that is analogous to that in RA, and it is a candidate biomarker to distinguish PsA from healthy individuals and from patients with OA and gout.

show abstract

Section: Resultsmentioning

confidence: 99%

Differential gene and protein expression of chemokines and cytokines in synovial fluid of patients with arthritis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…IL-17A is a key driver proinflammatory cytokine in psoriasis pathogenesis. 10-12 It activates epidermal hyperplasia, keratinocyte proliferation, and dermal infiltration of leukocytes. In addition, keratinocytes trigger numerous inflammatory circuits, leading to amplification of psoriasis inflammation.…”

Section: Introductionmentioning

confidence: 99%

Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis

Ryoo

Yang

et al. 2016

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

“…Studies have shown that the new generation of monoclonal antibodies, such as IL-12/23, IL-23, and IL-17A inhibitors, could reverse the clinical, histological, and molecular characteristics of PsO in approximately 70–80% of patients, compared with only 45–50% with TNF-α antagonists ( Chiricozzi and Krueger, 2013 ; Levin and Gottlieb, 2014 ). IL-17A has been identified as a key driver of pro-inflammatory cytokines in PsO pathogenesis ( Helliwell and Coates, 2015 ; Mease et al, 2015 ; Ryoo et al, 2016 ).…”

Section: Introductionmentioning

confidence: 99%

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System

Shu

Ding²,

Liu³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Purpose: Secukinumab was approved for the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, the long-term safety of secukinumab in large sample population was unknown. The current study was to evaluate the secukinumab-assocaited adverse events (AEs) through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS).Methods: Reports in the FAERS from the first quarter of 2015 (FDA approval of secukinumab) to the third quarter of 2021 were collected and analyzed. Disproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS) algorithms, were employed in data mining to quantify the signals of secukinumab-related AEs.Results: A total of 89,228 reports of secukinumab as the “primary suspected (PS)” and 254,886 AEs induced by secukinumab were identified. Secukinumab-induced AE occurrence targeted 27 system organ classes (SOCs). A total of 257 signals of secukinumab-induced AEs in 19 SOCs were detected after conforming to the four algorithms simultaneously. Common significant signals of infections, respiratory disorders, skin and subcutaneous tissue disorders, immune system disorders, and ear and labyrinth disorders have emerged. Unexpected significant AEs such as injection site pain, vessel puncture site haemorrhage, arthralgia, hypokinesia, Bell’s palsy, parotid gland enlargement, and stress might also occur. The median onset time of secukinumab-associated AEs was 56 days (interquartile range [IQR] 5–214 days), and most of the onsets occurred within the first 1, 2, 3, and 4 months after initiation of secukinumab.Conclusion: Our study found potential new AE signals and provided a broader understanding of secukinumab’s safety profiles, supporting its rational use in chronic systemic inflammatory diseases.

show abstract

Interleukin-17 inhibition in psoriatic arthritis

Cited by 5 publications

References 9 publications

Differential gene and protein expression of chemokines and cytokines in synovial fluid of patients with arthritis

Differential gene and protein expression of chemokines and cytokines in synovial fluid of patients with arthritis

Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System

Contact Info

Product

Resources

About